FDA OKs Mirdametinib for Neurofibromatosis Type 1

(MedPage Today) — The FDA on Tuesday approved mirdametinib (Gomekli) for adults and kids ages 2 and up with neurofibromatosis type 1 (NF1).
Approval of the MEK inhibitor is specifically for patients who have symptomatic plexiform neurofibromas…